Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
AQ-13 veelbelovend medicijn tegen resistente ‘Plasmodium falciparum’
sep 2017 | Parasitaire infecties